Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size

International Journal of Radiation Oncology Biology Physics

Volumn 79, Issue 5, 2011, Pages 1318-1322

  Nguyen, Paul L ^a,b   Chen, Ming H ^c   Choueiri, Toni K ^a,b   Hoffman, Karen E ^d   Hu, Jim C ^a,b   Martin, Neil E ^a,b   Beard, Clair J ^a,b   Dosoretz, Daniel E ^e   Moran, Brian J ^f   Katin, Michael J ^e   Braccioforte, Michelle H ^f   Ross, Rudi ^e   Salenius, Sharon A ^e   Kantoff, Philip W ^a,b   D'Amico, Anthony V ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e 21ST CENTURY ONCOLOGY   (United States)

^f Prostate Cancer Foundation of Chicago   (United States)

Author keywords

All cause mortality; Brachytherapy; Prostate cancer; Prostate volume; Small volume

Indexed keywords

ALL-CAUSE MORTALITY; BRACHYTHERAPY; PROSTATE CANCER; PROSTATE VOLUME; SMALL VOLUME;

ONCOLOGY; RADIOTHERAPY;

DISEASES;

ANTIANDROGEN; GONADORELIN AGONIST;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RISK FACTOR;

AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; CAUSE OF DEATH; FOLLOW-UP STUDIES; HUMANS; MALE; ORGAN SIZE; PROSTATE; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS;

EID: 79952694014     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.01.023     Document Type: Article

References (11)

1. Wang H, Wallner K, Sutlief S, et al. Transperineal brachytherapy in patients with large prostate glands. Int J Cancer 2000;90:199-205.
2. Nag S, Beyer D, Friedland J, et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999;44:789-799. (Pubitemid 29284127)
3. Bellon J, Wallner K, Ellis W, et al. Use of pelvic CT scanning to evaluate pubic arch interference of transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999;43:579-581. (Pubitemid 29107178)
4. Loblaw DA, Wallner K, Dibiase S, et al. Brachytherapy in patients with small prostate glands. Tech Urol 2000;6:64-69. (Pubitemid 30227177)
5. Merrick GS, Butler WM, Dorsey AT, et al. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation. Tech Urol 2001;7:233-240. (Pubitemid 32880244)
6. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;53:457-481.
7. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509.
8. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420-2425. (Pubitemid 46999213)
9. Nanda A, Chen MH, Braccioforte MH, et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009;302:866-873.
10. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008;93:68-75.
11. Yadav R, Tu JJ, Jhaveri J, et al. Prostate volume and the incidence of extraprostatic extension: Is there a relation? J Endourol 2009;23:383-386.